Andy I. Chen

3.5k total citations · 1 hit paper
38 papers, 1.5k citations indexed

About

Andy I. Chen is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Andy I. Chen has authored 38 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 19 papers in Oncology and 10 papers in Genetics. Recurrent topics in Andy I. Chen's work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CAR-T cell therapy research (9 papers). Andy I. Chen is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CAR-T cell therapy research (9 papers). Andy I. Chen collaborates with scholars based in United States, Italy and Poland. Andy I. Chen's co-authors include Arlene H. Sharpe, Veronika Bachanová, Patrick J. Stiff, John Sweetenham, Muneer H. Abidi, Tamás Masszi, Jerzy Hołowiecki, Anna Sureda, Jan Walewski and Craig H. Moskowitz and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Andy I. Chen

36 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 477 citations Craig H. Moskowitz, Auayporn Nademanee et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andy I. Chen United States	14	829	797	552	284	278	38	1.5k
Jocelyn Maragulia United States	16	993 1.2×	581 0.7×	287 0.5×	465 1.6×	325 1.2×	37	1.3k
Carla Casulo United States	19	1.3k 1.6×	1.1k 1.4×	400 0.7×	257 0.9×	555 2.0×	95	1.9k
Cinzia Pellegrini Italy	20	1.1k 1.3×	519 0.7×	317 0.6×	302 1.1×	294 1.1×	85	1.4k
Tatyana Feldman United States	23	1.5k 1.8×	1.3k 1.6×	463 0.8×	450 1.6×	422 1.5×	159	2.0k
Stephanie Sasse Germany	23	753 0.9×	819 1.0×	624 1.1×	258 0.9×	153 0.6×	48	1.6k
Tycel Phillips United States	22	956 1.2×	899 1.1×	367 0.7×	113 0.4×	554 2.0×	149	1.6k
Daisuke Ennishi Japan	20	958 1.2×	656 0.8×	253 0.5×	263 0.9×	452 1.6×	109	1.5k
Dirk Huebner United States	15	1.4k 1.6×	1.1k 1.4×	261 0.5×	499 1.8×	330 1.2×	44	1.8k
Anne Beaven United States	19	556 0.7×	511 0.6×	209 0.4×	148 0.5×	170 0.6×	89	956
Francesco Zallio Italy	18	853 1.0×	682 0.9×	400 0.7×	137 0.5×	243 0.9×	41	1.3k

Countries citing papers authored by Andy I. Chen

Since Specialization

Citations

This map shows the geographic impact of Andy I. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy I. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy I. Chen more than expected).

Fields of papers citing papers by Andy I. Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy I. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy I. Chen. The network helps show where Andy I. Chen may publish in the future.

Co-authorship network of co-authors of Andy I. Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Andy I. Chen. A scholar is included among the top collaborators of Andy I. Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy I. Chen. Andy I. Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riedell, Peter A., Loretta J. Nastoupil, Alejandro Luna, et al.. (2024). Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Advances. 9(5). 1232–1241. 6 indexed citations

Ahmed, Nausheen, Forat Lutfi, David L. Porter, et al.. (2024). Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Advances. 8(20). 5346–5354. 13 indexed citations

Bubalo, Joseph, et al.. (2023). A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation. Journal of Oncology Pharmacy Practice. 30(2). 304–312. 3 indexed citations

Bhaskar, Shakthi, David L. Porter, Stephen J. Schuster, et al.. (2022). Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Advances. 7(17). 4765–4772. 14 indexed citations

Tilly, Hervé, Franck Morschhauser, Nancy L. Bartlett, et al.. (2019). Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. The Lancet Oncology. 20(7). 998–1010. 93 indexed citations

Byrd, John C., Stephen D. Smith, Nina D. Wagner‐Johnston, et al.. (2018). First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 9(16). 13023–13035. 67 indexed citations

Chen, Andy I., et al.. (2018). Acute promyelocytic leukemia presenting with features of metastatic osseous disease. Leukemia Research Reports. 9. 36–37. 2 indexed citations

Sweetenham, John, Jan Walewski, Tamás Masszi, et al.. (2016). Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Biology of Blood and Marrow Transplantation. 22(3). S36–S37. 12 indexed citations

Sweetenham, John, Jan Walewski, Auayporn Nademanee, et al.. (2015). Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Blood. 126(23). 3172–3172. 21 indexed citations

10.

Moskowitz, Craig H., Auayporn Nademanee, Tamás Masszi, et al.. (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 385(9980). 1853–1862. 477 indexed citations breakdown →

11.

Moskowitz, Craig H., Tamás Masszi, Edward Agura, et al.. (2014). The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma. Blood. 124(21). 673–673. 11 indexed citations

12.

Chen, Andy I., Craig Okada, Stephen E. Spurgeon, et al.. (2014). Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma. Blood. 124(21). 3993–3993. 3 indexed citations

13.

Chen, Andy I., et al.. (2013). Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leukemia & lymphoma. 55(3). 583–587. 16 indexed citations

14.

Advani, Ranjana H., Daniel Lebovic, Mark W. Brunvand, et al.. (2012). A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood. 120(21). 59–59. 11 indexed citations

15.

Spurgeon, Stephen E., Andy I. Chen, Craig Okada, et al.. (2011). A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma. Blood. 118(21). 441–441. 4 indexed citations

16.

Chen, Andy I. & Ranjana H. Advani. (2008). Beyond the Guidelines in the Treatment of Peripheral T-Cell Lymphoma: New Drug Development. Journal of the National Comprehensive Cancer Network. 6(4). 428–435. 8 indexed citations

17.

Chen, Andy I., Alex McMillan, Robert S. Negrin, Sandra J. Horning, & Ginna G. Laport. (2008). Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience. Biology of Blood and Marrow Transplantation. 14(7). 741–747. 80 indexed citations

18.

Chen, Andy I., Alex McMillan, Robert S. Negrin, Sandra J. Horning, & Ginna G. Laport. (2007). Long Term Results of Autologous Hematopoietic Cell Transplantation (AHCT) for Peripheral T Cell Lymphoma: The Stanford Experience.. Blood. 110(11). 1906–1906. 3 indexed citations

19.

He, Hongzhen, et al.. (2002). Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. European Journal of Immunology. 32(10). 2874–2880. 93 indexed citations

20.

Chen, Andy I., Alexander J. McAdam, Janet E. Buhlmann, et al.. (1999). Ox40-Ligand Has a Critical Costimulatory Role in Dendritic Cell:T Cell Interactions. Immunity. 11(6). 689–698. 254 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact